Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study.
Caregivers
Chronic
Hyperoxaluria
Kidney Failure
Kidney Stones
Oxalosis
Primary
Qualitative Research
Quality of Life
SARS-CoV-2
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
26 10 2023
26 10 2023
Historique:
received:
27
03
2023
accepted:
13
10
2023
medline:
30
10
2023
pubmed:
27
10
2023
entrez:
26
10
2023
Statut:
epublish
Résumé
Without effective intervention, primary hyperoxaluria type 1 (PH1) causes oxalate-induced kidney damage, leading to end-stage kidney disease and serious complications throughout the body. Although PH1 carries a heavy burden that impacts quality of life, literature on the experiences of those living with PH1 and caring for patients with PH1 is limited. This study aimed to describe the diagnostic journey in PH1 and characterize patients' and caregivers' self-reported experiences throughout the disease course. This was an observational study involving in-depth, semi-structured telephone interviews. Dominant trends were assessed using constant comparative analysis to identify themes in interviewees' descriptions of their experiences. Individuals aged ≥ 12 years and caregivers of children aged 6-17 years with genetically confirmed PH1 were eligible. Informed consent/assent and ability to read and speak English were required. Interviewees (16 patients, 12 caregivers) reported a prolonged diagnostic journey due to low disease awareness, among other factors. Upon diagnosis, PH1 was frequently symptomatic, typically involving kidney stone-related symptoms but also potentially symptoms arising beyond the kidneys. PH1 most commonly led to worry and social impairment in adolescents, impaired physical function in adults, and a range of impacts on caregivers. In late-stage disease, dialysis was the most burdensome aspect of living with PH1 (due to time requirements, limitations from living with a catheter, etc.), and this burden was exacerbated by the COVID-19 pandemic. Benefits desired from PH1 management included reductions in laboratory measures of oxalate burden, kidney stone and urination frequency, and oxalate-related skin ulcers. PH1 greatly impacts patients' and caregivers' lives, primarily due to burdensome disease manifestations and associated emotional, physical, and practical impacts, as well as disease management challenges - particularly those related to dialysis in late-stage disease.
Sections du résumé
BACKGROUND
Without effective intervention, primary hyperoxaluria type 1 (PH1) causes oxalate-induced kidney damage, leading to end-stage kidney disease and serious complications throughout the body. Although PH1 carries a heavy burden that impacts quality of life, literature on the experiences of those living with PH1 and caring for patients with PH1 is limited. This study aimed to describe the diagnostic journey in PH1 and characterize patients' and caregivers' self-reported experiences throughout the disease course.
METHODS
This was an observational study involving in-depth, semi-structured telephone interviews. Dominant trends were assessed using constant comparative analysis to identify themes in interviewees' descriptions of their experiences. Individuals aged ≥ 12 years and caregivers of children aged 6-17 years with genetically confirmed PH1 were eligible. Informed consent/assent and ability to read and speak English were required.
RESULTS
Interviewees (16 patients, 12 caregivers) reported a prolonged diagnostic journey due to low disease awareness, among other factors. Upon diagnosis, PH1 was frequently symptomatic, typically involving kidney stone-related symptoms but also potentially symptoms arising beyond the kidneys. PH1 most commonly led to worry and social impairment in adolescents, impaired physical function in adults, and a range of impacts on caregivers. In late-stage disease, dialysis was the most burdensome aspect of living with PH1 (due to time requirements, limitations from living with a catheter, etc.), and this burden was exacerbated by the COVID-19 pandemic. Benefits desired from PH1 management included reductions in laboratory measures of oxalate burden, kidney stone and urination frequency, and oxalate-related skin ulcers.
CONCLUSIONS
PH1 greatly impacts patients' and caregivers' lives, primarily due to burdensome disease manifestations and associated emotional, physical, and practical impacts, as well as disease management challenges - particularly those related to dialysis in late-stage disease.
Identifiants
pubmed: 37884879
doi: 10.1186/s12882-023-03365-1
pii: 10.1186/s12882-023-03365-1
pmc: PMC10604408
doi:
Substances chimiques
Oxalates
0
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
319Informations de copyright
© 2023. The Author(s).
Références
Urology. 2021 Oct;156:e147-e149
pubmed: 33774044
Nephrol Ther. 2017 May;13(3):176-182
pubmed: 28161266
Pediatr Nephrol. 2013 Dec;28(12):2273-81
pubmed: 23494551
N Engl J Med. 2021 Apr 1;384(13):1216-1226
pubmed: 33789010
Transplantation. 2021 Apr 1;105(4):e46-e47
pubmed: 33760795
Nephrol Dial Transplant. 2012 May;27(5):1729-36
pubmed: 22547750
Clin J Am Soc Nephrol. 2009 Jun;4(6):1057-64
pubmed: 19423570
N Engl J Med. 2013 Aug 15;369(7):649-58
pubmed: 23944302
Clin J Am Soc Nephrol. 2020 Jul 1;15(7):1056-1065
pubmed: 32165440
Nephrol Dial Transplant. 2021 Jul 23;36(8):1464-1473
pubmed: 32810261
Endocrinol Metab Clin North Am. 2002 Dec;31(4):927-49
pubmed: 12474639
Kidney Int. 2014 Dec;86(6):1197-204
pubmed: 24988064
Kidney Int Rep. 2020 Sep 24;5(12):2136-2145
pubmed: 33305106
Nephrol Dial Transplant. 2012 Oct;27(10):3855-62
pubmed: 22844106
Int J Nephrol Renovasc Dis. 2012;5:151-63
pubmed: 23293534
Nat Rev Urol. 2022 Mar;19(3):137-146
pubmed: 34880452
Kidney Int. 2010 Mar;77(5):443-9
pubmed: 20016466
Front Med (Lausanne). 2021 Sep 20;8:703305
pubmed: 34616753
Clin J Am Soc Nephrol. 2020 Jul 1;15(7):909-911
pubmed: 32165441
J Am Soc Nephrol. 2015 Oct;26(10):2559-70
pubmed: 25644115